Ipamorelin: uses, research, and legal status

What is Ipamorelin?

Ipamorelin is a growth hormone secretagogue that acts on the ghrelin receptor. It is considered relatively selective, meaning it prompts growth-hormone release with comparatively little effect on hormones like cortisol and prolactin.

It is not FDA-approved and is among the peptides under the 2026 compounding review.

How it is thought to work

Ipamorelin stimulates the pituitary to release growth hormone in a pulse-like fashion. Its selectivity is the main reason it is often preferred over older secretagogues in research and clinical-interest settings.

What the research shows

Studies have examined its effect on growth-hormone release. As with related peptides, large long-term human outcome trials are limited.

Studied uses

• Supporting natural growth-hormone release
• Body-composition and recovery protocols
• Sleep quality (reported anecdotally)

Legal status in 2026

Ipamorelin is not FDA-approved and is among the peptides under federal review in 2026. No rule has changed yet, and it would remain prescription-only even if reclassified.

How to access Ipamorelin legitimately

A licensed provider assesses candidacy and, where permitted, prescribes through a licensed compounding pharmacy, monitoring response over time.

PeptideForward can match you with vetted telehealth providers who handle these therapies through legitimate channels. The eligibility check takes about five minutes and there is no cost to see if you are a candidate.

Frequently asked questions

Why is ipamorelin described as selective? It prompts growth-hormone release with relatively little impact on cortisol and prolactin compared with some older peptides.

Is it legal now? It is not approved. Where permitted it requires a prescription, and its compounding status is under 2026 review.

Does PeptideForward sell it? No. We are an education and matching service only.